Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 18,832 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $58.00, for a total transaction of $1,092,256.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Clay B. Siegall also recently made the following trade(s):

  • On Monday, September 11th, Clay B. Siegall sold 18,832 shares of Seattle Genetics stock. The shares were sold at an average price of $53.49, for a total transaction of $1,007,323.68.
  • On Monday, August 28th, Clay B. Siegall sold 25,506 shares of Seattle Genetics stock. The shares were sold at an average price of $47.89, for a total transaction of $1,221,482.34.

Seattle Genetics, Inc. (NASDAQ:SGEN) opened at $59.29 on Friday. Seattle Genetics, Inc. has a fifty-two week low of $45.31 and a fifty-two week high of $73.99.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.23. The firm had revenue of $135.29 million during the quarter, compared to analysts’ expectations of $112.76 million. Seattle Genetics had a negative return on equity of 32.41% and a negative net margin of 26.53%. Seattle Genetics’s quarterly revenue was up 27.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.23) EPS. equities research analysts anticipate that Seattle Genetics, Inc. will post -0.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Seattle Genetics, Inc. (SGEN) Insider Sells $1,092,256.00 in Stock” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/insider-selling-seattle-genetics-inc-sgen-insider-sells-1092256-00-in-stock/1708716.html.

Several research analysts recently weighed in on the stock. Cantor Fitzgerald set a $46.00 target price on shares of Seattle Genetics and gave the company a “hold” rating in a research note on Wednesday, August 16th. Royal Bank Of Canada upped their price objective on shares of Seattle Genetics from $68.00 to $69.00 and gave the company an “outperform” rating in a research note on Monday. BidaskClub downgraded shares of Seattle Genetics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Cowen and Company reaffirmed a “hold” rating on shares of Seattle Genetics in a research note on Sunday, October 29th. Finally, Morgan Stanley upped their price objective on shares of Seattle Genetics from $64.00 to $69.00 and gave the company an “overweight” rating in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $63.53.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SGEN. Manning & Napier Advisors LLC purchased a new position in Seattle Genetics in the 3rd quarter worth approximately $140,098,000. Capital International Investors boosted its holdings in Seattle Genetics by 63.7% in the 3rd quarter. Capital International Investors now owns 4,460,246 shares of the biotechnology company’s stock worth $242,682,000 after acquiring an additional 1,735,657 shares during the period. Janus Henderson Group PLC boosted its holdings in Seattle Genetics by 8,672.2% in the 2nd quarter. Janus Henderson Group PLC now owns 704,673 shares of the biotechnology company’s stock worth $36,460,000 after acquiring an additional 696,640 shares during the period. Pictet Asset Management Ltd. boosted its holdings in Seattle Genetics by 79.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,266,426 shares of the biotechnology company’s stock worth $68,906,000 after acquiring an additional 560,110 shares during the period. Finally, Capital Guardian Trust Co. boosted its holdings in Seattle Genetics by 82.2% in the 3rd quarter. Capital Guardian Trust Co. now owns 1,064,300 shares of the biotechnology company’s stock worth $57,909,000 after acquiring an additional 480,044 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.